Vaccine Institute, Institute for Infection and Immunity, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.
Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, UK.
Lancet Infect Dis. 2017 Jul;17(7):e223-e234. doi: 10.1016/S1473-3099(17)30232-3. Epub 2017 Apr 19.
Group B streptococcus and respiratory syncytial virus are leading causes of infant morbidity and mortality worldwide. No licensed vaccines are available for either disease, but vaccines for both are under development. Severe respiratory syncytial virus disease can be prevented by passively administered antibody. The presence of maternal IgG antibody specific to respiratory syncytial virus is associated with reduced prevalence and severity of respiratory syncytial virus disease in the first few weeks of life, whereas maternal serotype-specific anticapsular antibody is associated with protection against both early-onset and late-onset group B streptococcus disease. Therefore, vaccination in pregnancy might protect infants against both diseases. This report describes what is known about immune protection against group B streptococcus and respiratory syncytial virus, identifies knowledge gaps regarding the immunobiology of both diseases, and aims to prioritise research directions in maternal immunisation.
B 群链球菌和呼吸道合胞病毒是全球导致婴儿发病和死亡的主要原因。目前这两种疾病均无获得许可的疫苗，但针对这两种疾病的疫苗正在研发中。呼吸道合胞病毒严重疾病可通过被动给予抗体来预防。存在针对呼吸道合胞病毒的母体 IgG 抗体与生命最初几周呼吸道合胞病毒疾病的发生率和严重程度降低相关，而母体血清型特异性抗荚膜抗体与预防早发型和晚发型 B 群链球菌疾病相关。因此，妊娠期接种疫苗可能会保护婴儿免受这两种疾病的侵害。本报告描述了针对 B 群链球菌和呼吸道合胞病毒的免疫保护作用，确定了这两种疾病的免疫生物学相关知识空白，并旨在确定母体免疫接种的研究重点。
